Denosumab is primarily used in oncology to manage bone-related complications. It is approved for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors, such as breast cancer and prostate cancer. Additionally, it is used to treat giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
